This double-blind, placebo-controlled, full cross-over trial (n=30) will study the effects of psilocybin (10mg/70kg) on brain activity and thought dynamics in healthy volunteers.
Conducted by Johns Hopkins University, this research aims to understand how psilocybin, a psychoactive compound in mushrooms, affects creativity, memory, and brain response to natural stimuli. Using EEG, MRI, and various cognitive tasks, the study seeks to explore the acute psychological and neural effects of psilocybin, potentially aiding in the optimisation of psychedelic medicine and deepening the understanding of consciousness.
Participants, aged 18-75, will receive both psilocybin and placebo in a counter-balanced order, with primary measures including word frequency during free association tasks, memory sensitivity, and EEG alpha band power. The study began on 3rd March 2022, and is expected to complete by 31st December 2024.
Trial Details
This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity.NCT Number NCT05301608
Sponsors & Collaborators
Johns Hopkins UniversityJohns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.